The erythroid line is certainly one of the best described of haematopoiesis and has been for a long time. The molecular mechanisms regulating its differentiation have formed the subject of numerous studies. Surprisingly, however, the enucleation which characterizes the final stage of maturation of the red blood cell (RBC) still remains very largely unexplained. What a paradox for a cell line of which the physiological role is major (transport of oxygen by haemoglobin), the pathology multidisciplinary (haemoglobinopathies, haemopathies, parasitic infections) and the therapeutic interest vital (blood transfusion).
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One of the principal characteristics of the human RBC is in fact that it is the only cell to have a prolonged life span (120 days) despite the absence of a nucleus. The mechanisms of enucleation are suspected but have not been formally established due to a lack of experimental conditions permitting the massive ex vivo generation of RBC. Such conditions must indeed satisfy three requirements: the massive amplification of primitive haematopoietic stem cells (HSC), the controlled induction of exclusive differentiation to the erythroid line and the completion of terminal maturation to the stage of enucleated cells. If it is relatively easy to obtain selective erythroid differentiation, the data of the literature nevertheless show either strong cell proliferation without terminal maturation, or enucleation but with reduced cell amplification. No ex vivo system has yet been described which allows one to obtain both massive proliferation and enucleation of all the erythroblasts.
We have previously reported (Nature biotechnology, 2002; 5; 464-472) 
Conclusion
This new concept of "cultured RBC" provides an innovative tool to elucidate the physiopathological mechanisms of erythropoiesis and opens up potentially considerable therapeutic perspectives, notably in the field of blood transfusion. The hopes engendered by this new approach to cell therapy should become concrete reality in the relatively near future, given the right conditions of Research and Development.
